Entry |
|
Name |
HRAS-overexpression to ERK signaling pathway
|
Definition |
HRAS* -> RAF -> MEK -> ERK -> MSK1 -> MYC |
Expanded |
3265v1 -> (369,673,5894) -> (5604,5605) -> (5594,5595) -> 9252 -> 4609 |
Class |
|
Type |
Variant
|
Pathway |
|
Disease |
|
Gene |
3265 | HRAS; HRas proto-oncogene, GTPase |
369 | ARAF; A-Raf proto-oncogene, serine/threonine kinase |
673 | BRAF; B-Raf proto-oncogene, serine/threonine kinase |
5894 | RAF1; Raf-1 proto-oncogene, serine/threonine kinase |
5604 | MAP2K1; mitogen-activated protein kinase kinase 1 |
5605 | MAP2K2; mitogen-activated protein kinase kinase 2 |
5594 | MAPK1; mitogen-activated protein kinase 1 |
5595 | MAPK3; mitogen-activated protein kinase 3 |
9252 | RPS6KA5; ribosomal protein S6 kinase A5 |
4609 | MYC; MYC proto-oncogene, bHLH transcription factor |
|
Variant |
3265v1 (HRAS*) HRAS overexpression
|
Reference |
|
Authors |
Mitra AP, Datar RH, Cote RJ. |
Title |
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. |
Journal |
|
Reference |
|
Authors |
Wolff EM, Liang G, Jones PA. |
Title |
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. |
Journal |
|